1. Basic information disclosure policy
Solasia Pharma K.K. (hereinafter the "Company") endeavors to actively, fairly and appropriately disclose company information to shareholders, investors and other stakeholders on a timely basis. In order to ensure the transparency of our management, we maintain a basic policy of effectively ensuring better understanding and recognition of our organization.
2. Information disclosure standards
The Company discloses information in a manner that ensures transparency, freedom from bias, timeliness, continuity and compliance with the Financial Instruments and Exchange Act, other laws and regulations and rules regarding the timely disclosure of corporate information stipulated in the "Securities Listing Regulations" (hereafter "Timely Disclosure Rules") of the Tokyo Stock Exchange (hereafter "TSE"). In addition, the Company actively and equitably discloses information judged to be effective for the facilitation of understanding, even if this information is not governed by laws, ordinances or Timely Disclosure Rules. However, we refrain from disclosing personal information, client information or information that may infringe upon the rights of any related party.
3. Information disclosure methods
In cases when the timely disclosure of information must be conducted as specified in the TSE regulations, the Company discloses this information using the Timely Disclosure Network ("TDnet") operated by the TSE.
The Company conducts disclosure governed by the Financial Instruments and Exchange Act using the Electronic Disclosure for Investors' Network ("EDINET"), an electronic system provided by the Financial Services Agency for the disclosure of securities reports and other documents. We also publicly disclose relevant information that is not subject to the Timely Disclosure Rules through various methods, including our corporate website.
4. Insider trading prevention
In accordance with internal policies, the Company will not provide information to shareholders and investors before it has announced this information publicly. The Company tightly controls undisclosed information while endeavoring to prevent its misuse and forestall insider trading.
5. Handling of forward-looking statements
When the Company discloses corporate strategies, business policies, earnings forecasts and other forward-looking statements, it clearly indicates that these statements reflect expectations and calculations it deemed accurate based on information available at the time of disclosure. The accuracy of these statements is susceptible to potential impact stemming from various risks and uncertainties.
6. Treatment of ambiguous information
The Company, in principle, does not comment or respond to queries concerning ambiguous information such as market rumors. However, the Company will deliver prompt and sufficient responses when it deems that explanations for shareholders and investors are warranted or when it receives inquiries directly from the TSE.